These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34013740)

  • 1. Representation of Women Authors in Trials of Lipid-Lowering Therapy.
    Raghu Subramanian C; Khan SU; Lone AN; Reza N; DeFilippis EM; Gulati M; Michos ED
    J Am Heart Assoc; 2021 Jun; 10(11):e020663. PubMed ID: 34013740
    [No Abstract]   [Full Text] [Related]  

  • 2. Have we reached the bottom of the bottomless pit- lessons from the recent lipid-lowering trials?
    Bansal M; Agarwala R
    Indian Heart J; 2018; 70(3):331-334. PubMed ID: 29961445
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapy and clinical trials.
    Seed M
    Curr Opin Lipidol; 1996 Oct; 7(5):U168-72. PubMed ID: 8937532
    [No Abstract]   [Full Text] [Related]  

  • 4. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
    Temple R
    Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896
    [No Abstract]   [Full Text] [Related]  

  • 5. Results of the REVEAL study. Why Should we not welcome a new lipid lowering agent?
    Masana L
    Clin Investig Arterioscler; 2017; 29(6):278-279. PubMed ID: 29173491
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipids and antithrombotic treatment.
    Agewall S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):71. PubMed ID: 32176294
    [No Abstract]   [Full Text] [Related]  

  • 7. Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry.
    Navar AM; Wang TY; Goldberg AC; Robinson JG; Roger VL; Wilson PF; Virani SS; Elassal J; Lee LV; Webb LE; Peterson E
    Am Heart J; 2015 Nov; 170(5):865-71. PubMed ID: 26542493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Terje Pedersen: a pioneer trialist in preventive cardiology.
    Morris K
    Lancet; 2010 Feb; 375(9716):717. PubMed ID: 20189014
    [No Abstract]   [Full Text] [Related]  

  • 9. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk.
    Graham I; Shear C; De Graeff P; Boulton C; Catapano AL; Stough WG; Carlsson SC; De Backer G; Emmerich J; Greenfeder S; Kim AM; Lautsch D; Nguyen T; Nissen SE; Prasad K; Ray KK; Robinson JG; Sasiela WJ; Bruins Slot K; Stroes E; Thuren T; Van der Schueren B; Velkovski-Rouyer M; Wasserman SM; Wiklund O; Zouridakis E;
    Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):119-127. PubMed ID: 29194462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-intensity lipid-lowering regimens in patients with stable coronary artery disease: the intriguing question of all-cause mortality.
    Danchin N; Simon T
    Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):328-330. PubMed ID: 31539045
    [No Abstract]   [Full Text] [Related]  

  • 11. Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial.
    Giugliano RP; Mach F; Zavitz K; Kurtz C; Schneider J; Wang H; Keech A; Pedersen TR; Sabatine MS; Sever PS; Honarpour N; Wasserman SM; Ott BR;
    Clin Cardiol; 2017 Feb; 40(2):59-65. PubMed ID: 28207168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipidology.
    Nicholls SJ
    Cardiol Clin; 2018 May; 36(2):xiii. PubMed ID: 29609763
    [No Abstract]   [Full Text] [Related]  

  • 13. Landmark lipid-lowering trials in the primary prevention of cardiovascular disease.
    Chrispin J; Martin SS; Hasan RK; Joshi PH; Minder CM; McEvoy JW; Kohli P; Johnson AE; Wang L; Blaha MJ; Blumenthal RS
    Clin Cardiol; 2013 Sep; 36(9):516-23. PubMed ID: 23722477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Countering clinical inertia in lipid management: Expert workshop summary.
    Zullig LL; Egbuonu-Davis L; Trasy A; Oshotse C; Goldstein KM; Bosworth HB
    Am Heart J; 2018 Dec; 206():24-29. PubMed ID: 30290290
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular risk assessment and lipid modification: NICE guideline.
    Duerden M; O'Flynn N; Qureshi N
    Br J Gen Pract; 2015 Jul; 65(636):378-80. PubMed ID: 26120133
    [No Abstract]   [Full Text] [Related]  

  • 16. Ethnicity, lipids and cardiovascular disease.
    Gazzola K; Reeskamp L; van den Born BJ
    Curr Opin Lipidol; 2017 Jun; 28(3):225-230. PubMed ID: 28338521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More Nuanced Guidelines for Lipid Lowering to Prevent CVD.
    Shaughnessy AF
    Am Fam Physician; 2016 Jan; 93(1):59. PubMed ID: 26760843
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs.
    Butters J; Brown A; Griffith L; Kim S; Nicholls SJ
    Am J Cardiovasc Drugs; 2017 Dec; 17(6):447-452. PubMed ID: 28432573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
    Marrs JC; Saseen JJ
    Pharmacotherapy; 2010 Aug; 30(8):823-9. PubMed ID: 20653359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Ideal Lipid Report: A Need for Consensus.
    Pedro-Botet J; Rodríguez-Padial L; Brotons C; Esteban-Salán M; García-Lerín A; Pintó X; Lekuona I; Ordóñez-Llanos J
    Rev Esp Cardiol (Engl Ed); 2018 Jul; 71(7):512-514. PubMed ID: 29716842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.